July 24, 2015 (Shareholders Foundation) - An investigation on behalf of investors of XOMA Corp (NASDAQ:XOMA) shares over potential securities laws violations by XOMA and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of XOMA Corp (NASDAQ:XOMA) concerning whether a series of statements by XOMA regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

XOMA Corp reported that its annual Total Revenue declined from $35.45 million in 2013 to $18.87 million in 2014, while its respective Net Loss declined from $124.06 million to $38.30 million.

On July 22, 2015, XOMA Corp announced results From Phase 3 EYEGUARD(TM)-B Study. Xoma Corp said that a Phase III trial of its treatment (gevokizumab) for Behcet's disease in the eye missed the primary endpoint of time to first acute ocular exacerbation. The company announced that it will continue to work with its French partner, Servier, to conduct a thorough analysis of the data.

Shares of XOMA Corp (NASDAQ:XOMA) declined from $4.45 per share on July 21, 2015, to $0.88 per share on July 22, 2015.